Ruxolitinib for tocilizumab-refractory severe COVID-19 infection

Br J Haematol. 2020 Aug;190(4):e198-e200. doi: 10.1111/bjh.16979. Epub 2020 Jul 26.

Authors

Andrew J Innes^{1

2}, Lucy B Cook^{1

2}, Sasha Marks², Edward Bataillard², Christina Crossette-Thambiah², Gayathiri Sivasubramaniam³, Jane Apperley^{1

2}, Dragana Milojkovic^{1

2}

Affiliations

¹ Centre for Haematology, Department of Immunology & Inflammation, Imperial College London, London, UK.
² Department of Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
³ Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

No abstract available

Keywords: COVID-19; immunosupression; infection; transplant.

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Allografts
Antibodies, Monoclonal, Humanized / administration & dosage*
Blast Crisis / blood
Blast Crisis / therapy
COVID-19 / blood
COVID-19 Drug Treatment*
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
Male
Nitriles
Pyrazoles / administration & dosage*
Pyrimidines
SARS-CoV-2*
Severity of Illness Index

Substances

Antibodies, Monoclonal, Humanized
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
tocilizumab

Grants and funding